Ballard Victoria L T, Edelberg Jay M
GlaxoSmithKline, 709 Swedeland Road, UW2109, King of Prussia, PA 19406, USA.
J Mol Cell Cardiol. 2008 Oct;45(4):582-92. doi: 10.1016/j.yjmcc.2008.02.277. Epub 2008 Mar 4.
The discovery of extracardiac progenitor cells and resident cardiac stem cells in recent years has led to a great deal of interest in the development of therapeutic strategies that target these endogenous cell sources for promotion of cardiovascular repair mechanisms in the diseased heart. Cardiovascular risk increases with age and among many factors, the age-associated decline in cardiac and vascular regenerative capacity may contribute to the progressive deterioration of cardiovascular health. Thus, understanding the mechanisms which underlie the dysregulation of cardiac stem and progenitor cells may lead to the identification of novel targets and approaches to reverse this decline. In this review, we outline the current knowledge about cardiac stem and progenitor cells, their contribution to cardiovascular regenerative processes and factors that may affect their decreased function in aging individuals. Moreover, we describe the therapeutic strategies that are currently being tested in clinical trials as well as potential new avenues of investigation for the future.
近年来，心外祖细胞和心脏驻留干细胞的发现引发了人们对开发治疗策略的极大兴趣，这些策略旨在针对这些内源性细胞来源，促进患病心脏的心血管修复机制。心血管风险随年龄增长而增加，在众多因素中，与年龄相关的心脏和血管再生能力下降可能导致心血管健康的逐渐恶化。因此，了解心脏干细胞和祖细胞失调的机制可能有助于识别新的靶点和方法，以扭转这种下降趋势。在这篇综述中，我们概述了关于心脏干细胞和祖细胞的现有知识、它们对心血管再生过程的贡献以及可能影响其在衰老个体中功能下降的因素。此外，我们描述了目前正在临床试验中测试的治疗策略以及未来潜在的新研究途径。
